Dupont Capital Management’s Acceleron Pharma XLRN Stock Holding History

Dupont Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-23,200	Closed	-$3.99M	–	2060
2021 Q3	$3.99M	Buy	+23,200	New	+$3.03M	0.13%	151
2018 Q3	–	Sell	-15,488	Closed	-$751K	–	1052
2018 Q2	$751K	Buy	15,488 +10,677	+222%	+$389K	0.02%	614
2018 Q1	$188K	Buy	+4,811	New	+$205K	﹤0.01%	817
2017 Q2	–	Sell	-12,037	Closed	-$319K	–	1012
2017 Q1	$319K	Hold	12,037	–	–	0.01%	780
2016 Q4	$307K	Sell	12,037 -5,313	-31%	-$168K	0.01%	770
2016 Q3	$628K	Hold	17,350	–	–	0.01%	538
2016 Q2	$590K	Buy	+17,350	New	+$564K	0.01%	554

Dupont Capital Management's XLRN Position: Q4 2021 in Review

Dupont Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 23,200 shares — an estimated $3.99M sold.

Dupont Capital Management first reported a position in XLRN in Q2 2016 and held it in 7 quarters. The position peaked at $3.99M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Dupont Capital Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Dupont Capital Management sold 23,200 Acceleron Pharma shares in Q4 2021, an estimated $3.99M.
Dupont Capital Management first reported a position in Acceleron Pharma in Q2 2016 and held it in 7 quarters.
Dupont Capital Management's Acceleron Pharma position peaked at $3.99M in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Dupont Capital Management's 13F filing for Q4 2021, filed 31 Jan 2022.